Cadence Pharmaceuticals Inc. (CADX)

[surf1944]

Cadence Pharmaceuticals (CADX)

Notable Shareholders: Wellington Management Company LLP, Capital Research Global Investors
The company's main product is OFIRMEV (acetaminophen) injection that it in-licensed rights from Bristol-Myers Squibb (BMY) Company. This proprietary treatment is the first and only intravenous formulation of acetaminophen approved in the United States. In Europe, Bristol-Myers markets the same product under the trademark PERFALGAN. The US commercial launch occurred in January 2011. According to the company, there were 675 hospitals in the first 15 weeks of launch. Going forward, the company could see rapid, significant growth potential as US hospitals adopt IV acetaminophen. Unlike the European approach, which includes both IV acetaminophen and opioids to address pain, the US currently relies almost exclusively on opioids.

In 2010, CADX did not generate revenue and lost $56.64 million. In the most recent quarter the company reported revenues of $350,000 and net losses of $24.37 million as the burn rate accelerated. As of March 31, 2011, the company had cash and investments of $109 million.

Cadence's stock price peaked to $17 per share and dropped as low as $5 during the financial crisis before rebounding to current levels.

http://seekingalpha.com/article/271283-6-speculative-biotech-stocks-smart-money-loves?source=yahoo